Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug Read more →

AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates Read more →

Amgen sheds around 40 staffers amid continuing struggles Read more →